Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...
With the decision by the U.S. Food and Drug Administration and the European Commission to grant market authorization for Waskyratm, a gene therapy to treat Wiskott-Aldrich syndrome, AGC Biologics' ...
This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approvedMILAN--(BUSINESS WIRE)--#CGT--With the decision by ...
The global automated nucleic acid extraction market size was valued at US$ 3.6 Bn in 2025 and is projected to reach US$ 11.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback